Skip to content
stoqly

Zimmer Biomet

ZBH NYSE Health Care Equipment Financials FY2016–FY2025

Zimmer Biomet's revenue rose 7.2% to $8.2 billion in fiscal 2025. Its operating margin was 13.3%, down from 16.7% a year earlier. Free cash flow was $1.5 billion, up 13.7%. It paid out $677 million in dividends and buybacks, 46% of free cash flow. The diluted share count fell 2.5%.

Last close · Oct 23, 2026

$98.56

0.3%
Value it Compare
Revenue Total sales reported in the income statement.
$8.2B
7.2% vs prior year
Operating margin Operating income as a share of revenue.
13.3%
3.4 pts
Net income Profit after all expenses, interest and tax.
$705M
22.0%
Free cash flow Cash from operations minus capital spending.
$1.5B
13.7%
Return on capital After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
4.9%
1.3 pts
Market cap Last close times the latest diluted share count, so it is approximate.
$19.0B
Oct 23 close
P/E Last close divided by diluted earnings per share over the last four quarters.
23.9x
On $4.12 EPS (TTM)

What Zimmer Biomet does

No business description yet.

Legal name
ZIMMER BIOMET HOLDINGS, INC.
Fiscal year ends
December 31, 2025
Latest annual report
—
Accession · CIK
0001193125-26-059853
0001136869

Revenue and margins

Zimmer Biomet had $8.2B of revenue in fiscal 2025, up 7.2% on the year before.

Revenue
Revenue
Margins, % of revenue
Gross Operating Net FCF
Margins, % of revenue
Gross Operating Net FCF

Net income and earnings per share

From fiscal 2016 to 2025, diluted EPS grew 10.0% a year. Loss periods are shown in red.

Net income
Net income
Diluted EPS
Diluted EPS

Returns on capital

After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.

Return on capital, equity and assets (annual)
Return on capital Return on equity Return on assets

Cash flow

Free cash flow was $1.5B in fiscal 2025, 17.9% of revenue. Cash from operations minus capital spending.

Free cash flow
Free cash flow
Cash from operations vs capital spending
Cash from operations Capital spending
Cash from operations vs capital spending
Cash from operations Capital spending

Dividends, buybacks and share count

Zimmer Biomet returned $677M to shareholders in fiscal 2025, 46% of free cash flow. The diluted share count fell 2.6%.

Dividends and buybacks
Dividends Buybacks
Dividends and buybacks
Dividends Buybacks
Diluted shares outstanding (annual)

Value Zimmer Biomet yourself

Change the assumptions and see what they imply per share. These are models, not forecasts or price targets — the answer depends entirely on what you put in.

Discounted cash flow

Value per share

—

Adds net cash of −$6.9B and divides by 198.7M diluted shares. Ten years of cash flows plus a terminal value, discounted to today.

Earnings multiple

Value per share

—

Reference multiples: today 23.9x · peers 51.2x · sector 28.4x.

Balance sheet

Cash, debt and the ratios that show how comfortably Zimmer Biomet can carry it.

Cash vs debt (incl. leases)
Cash Debt
Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments $378M$376M$416M$526M$592M
Debt incl. finance leases $1.0B$5.7B$5.8B$6.2B$7.5B
Net debt / EBITDA 0.4x3.3x2.4x2.5x3.2x
Debt / equity 0.1x0.5x0.5x0.5x0.6x
Interest coverage 3.9x4.3x6.4x6.4x3.7x
Current ratio 1.4x1.9x1.6x1.9x2.0x
Quick ratio 0.8x1.0x0.8x1.0x1.1x
Total assets $23.5B$21.1B$21.5B$21.4B$23.1B
Total liabilities $10.8B$9.0B$9.0B$8.9B$10.4B
Shareholders' equity $12.7B$12.0B$12.5B$12.5B$12.7B
Net debt (− = net cash) $622M$5.3B$5.4B$5.7B$6.9B

Insider trades

Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. 'Plan' marks trades under a pre-arranged Rule 10b5-1 plan.

Bought, 12 months

$0.0M

0 insiders

Sold, 12 months

$1.6M

4 insiders

Of sales under plans

0%

$0.0M

DateInsiderTradeSharesPriceValueFiling
Sep 11, 2026 Kevin R ThornalGrp Pres-Global Business Sold 5,691 $92.95 $0.5M Form 4
Sep 4, 2026 Chad F PhippsSee remarks below. Sold 3,000 $98.35 $0.3M Form 4
May 29, 2026 Sang YiGroup President, Asia Pacific Sold 5,000 $82.64 $0.4M Form 4
Mar 12, 2026 Lori WinklerSVP and CHRO Sold 2,650 $94.66 $0.3M Form 4
Feb 12, 2026 Sang YiGroup President, Asia Pacific Sold 1,000 $96.49 $0.1M Form 4

Piotroski F-score

Nine pass/fail tests of profitability, funding and efficiency. 8–9 is strong, 0–2 weak.

TestFY23FY24FY25
Net income is positive ✓ ✓ ✓
Cash from operations is positive ✓ ✓ ✓
Return on assets rose ✓ ✕ ✕
Cash from operations exceeds net income ✓ ✓ ✓
Debt fell relative to assets ✕ ✕ ✕
Current ratio rose ✕ ✓ ✓
Share count didn't rise ✓ ✓ ✓
Gross margin rose ✓ ✕ ✕
Revenue rose relative to assets ✓ ✓ ✓
F-score 7 / 96 / 96 / 9
Accruals ratio −2.6%−2.8%−4.5%
Altman Z'' 3.964.253.96

Similar companies

Each company's latest fiscal year. Fiscal years end in different months, so periods don't line up exactly.

CompanyMarket capGrowthOp. marginFCF marginROICP/EF-score
Zimmer Biomet ZBH $19.0B 7.2% 13.3% 17.9% 4.9% 23.9x 6
Intuitive Surgical ISRG $159.0B 20.5% 29.3% 24.8% 20.9% 54.8x 5 Compare →
Edwards Lifesciences EW $51.4B 11.6% 20.8% 22.0% 15.7% 51.2x 5 Compare →
Baxter International BAX $13.1B 5.7% −2.7% 3.0% −1.4% — 5 Compare →
Steris STE $22.7B 8.7% 18.6% 16.4% 9.6% 28.4x 9 Compare →

10 years of figures

US$ millions unless stated. Hover a ratio's name for its definition.

Download CSV
Fiscal yearFY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue $7.7B $7.8B $7.9B $8.0B $6.1B $6.8B $6.9B $7.4B $7.7B $8.2B
Gross profit $5.3B $5.7B $5.7B $5.7B $4.3B $4.9B $4.9B $5.3B $5.5B $5.7B
Research and development $366M $370M $392M $449M $323M $436M $406M $459M $437M $459M
Operating income $821M $799M $33.8M $1.1B $83.1M $860M $696M $1.3B $1.3B $1.1B
Interest expense $358M $328M $227M $193M $193M $219M $162M $201M $201M $298M
Pretax income $400M $465M −$271M $906M −$105M $499M $404M $1.1B $1.0B $831M
Income tax $95.0M −$1.3B $108M −$226M −$96.0M $53.5M $112M $42.2M $131M $126M
Net income $306M $1.8B −$379M $1.1B −$139M $402M $231M $1.0B $904M $705M
Diluted EPS $1.51 $8.90 −$1.86 $5.47 −$0.67 $1.91 $1.10 $4.88 $4.43 $3.55
Diluted shares 0.20B 0.20B 0.20B 0.21B 0.21B 0.21B 0.21B 0.21B 0.20B 0.20B
Cash flow
Cash from operations $1.6B $1.6B $1.7B $1.6B $1.2B $1.5B $1.4B $1.6B $1.5B $1.7B
Capital expenditure $185M $156M $163M $207M $112M $144M $188M $291M $204M $225M
Free cash flow $1.4B $1.4B $1.6B $1.4B $1.1B $1.4B $1.2B $1.3B $1.3B $1.5B
Depreciation and amortization $1.0B $1.1B $1.0B $1.0B $898M $938M $926M $952M $996M $1.1B
Stock-based compensation $57.3M $53.7M $65.5M $84.3M $73.8M $76.0M $105M $99.8M $101M $90.2M
Acquisitions $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M
Share buybacks $416M $0.0M $0.0M $0.0M $0.0M $0.0M $126M $692M $868M $487M
Dividends paid $188M $194M $195M $197M $199M $200M $201M $201M $196M $190M
Dividends and buybacks $604M $194M $195M $197M $199M $200M $328M $893M $1.1B $677M
Balance sheet
Cash and short-term investments $634M $524M $543M $618M $802M $378M $376M $416M $526M $592M
Total debt $11.2B $10.1B $8.9B $8.2B $8.1B $1.0B $5.7B $5.8B $6.2B $7.5B
Finance lease liabilities $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M
Current assets $4.7B $4.6B $4.4B $4.7B $5.1B $4.9B $4.4B $4.6B $4.7B $5.1B
Current liabilities $2.4B $3.1B $2.4B $3.4B $2.6B $3.5B $2.4B $2.9B $2.5B $2.6B
Inventory $2.0B $2.1B $2.3B $2.4B $2.5B $2.1B $2.1B $2.4B $2.2B $2.3B
Property and equipment, net $2.0B $2.0B $2.0B $2.1B $2.0B $1.8B $1.9B $2.1B $2.0B $2.2B
Total assets $26.7B $26.0B $24.1B $24.6B $24.4B $23.5B $21.1B $21.5B $21.4B $23.1B
Total liabilities $17.0B $14.3B $12.9B $12.2B $12.2B $10.8B $9.0B $9.0B $8.9B $10.4B
Shareholders' equity $9.7B $11.7B $11.3B $12.4B $12.2B $12.7B $12.0B $12.5B $12.5B $12.7B
Margins
Gross margin 68.9% 72.7% 71.4% 71.8% 70.2% 71.3% 70.9% 71.8% 71.5% 69.7%
Operating margin 10.7% 10.2% 0.4% 14.3% 1.4% 12.6% 10.0% 17.3% 16.7% 13.3%
EBITDA margin 24.3% 23.9% 13.5% 26.9% 16.0% 26.3% 23.4% 30.2% 29.7% 26.6%
Net margin 4.0% 23.2% −4.8% 14.2% −2.3% 5.9% 3.3% 13.9% 11.8% 8.6%
FCF margin 18.9% 18.3% 20.0% 17.3% 17.8% 19.9% 16.8% 17.5% 16.9% 17.9%
Returns
Return on capital 3.1% 3.8% 0.1% 5.7% 0.3% 4.7% 3.3% 7.0% 6.2% 4.9%
Return on capital employed 3.3% 3.4% 0.2% 5.3% 0.4% 4.1% 3.6% 6.8% 6.9% 5.6%
Return on equity 3.1% 17.0% −3.3% 9.6% −1.1% 3.2% 1.9% 8.4% 7.3% 5.6%
Return on assets 1.1% 6.9% −1.5% 4.6% −0.6% 1.7% 1.0% 4.8% 4.2% 3.2%
Growth
Revenue growth 27.9% 1.8% 1.7% 0.6% −23.2% 11.4% 1.7% 6.6% 3.9% 7.2%
Net income growth 108.1% 492.9% −120.9% — −112.3% — −42.4% 342.5% −11.7% −22.0%
EPS growth 96.1% 489.4% −120.9% — −112.3% — −42.4% 343.6% −9.2% −19.9%
FCF growth 112.2% −1.5% 11.1% −13.0% −20.8% 24.1% −13.8% 10.5% 0.4% 13.7%
Share count change 6.6% 0.6% −0.1% 1.6% 0.2% 1.6% −0.1% −0.3% −2.8% −2.6%
Financial health
Net debt / EBITDA 5.7x 5.2x 7.8x 3.6x 7.5x 0.4x 3.3x 2.4x 2.5x 3.2x
Debt / equity 1.2x 0.9x 0.8x 0.7x 0.7x 0.1x 0.5x 0.5x 0.5x 0.6x
Interest coverage 2.3x 2.4x 0.2x 5.9x 0.4x 3.9x 4.3x 6.4x 6.4x 3.7x
Current ratio 2.0x 1.5x 1.8x 1.4x 2.0x 1.4x 1.9x 1.6x 1.9x 2.0x
Quick ratio 1.1x 0.8x 0.9x 0.7x 1.0x 0.8x 1.0x 0.8x 1.0x 1.1x
Capital allocation
Capex / revenue 2.4% 2.0% 2.1% 2.6% 1.8% 2.1% 2.7% 3.9% 2.7% 2.7%
Stock comp / revenue 0.8% 0.7% 0.8% 1.1% 1.2% 1.1% 1.5% 1.4% 1.3% 1.1%
Payouts / FCF 41.7% 13.6% 12.3% 14.3% 18.2% 14.8% 28.0% 69.2% 82.1% 46.0%
Quality scores
Piotroski F-score 4.0 6.0 6.0 7.0 4.0 7.0 6.0 7.0 6.0 6.0
Altman Z'' 2.4 2.7 2.8 3.1 3.1 3.3 3.7 4.0 4.3 4.0
Accruals ratio −4.9% 0.9% −8.5% −1.9% −5.5% −4.6% −5.1% −2.6% −2.8% −4.5%

Source: SEC EDGAR XBRL filings (CIK 0001136869). Data updated October 9, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only — not investment advice. Check the original filings before relying on any figure.

↑ ↓ to move · ↵ to open